MIDDLE EAST HEALTHCARE COMPANY Financials Middle East Healthcare Company
Equities
4009
SA141H01UKH9
Healthcare Facilities & Services
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 91.5 SAR | +0.44% |
|
-2.87% | +3.62% |
| Apr. 04 | Middle East Healthcare Company Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 31 | Middle East Healthcare Co. Reports Higher FY23 Profit, Revenue | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,734 | 3,226 | 2,913 | 2,342 | 8,127 | 8,422 | - | - |
| Enterprise Value (EV) 1 | 3,721 | 4,759 | 4,852 | 4,510 | 10,568 | 10,668 | 10,445 | 8,422 |
| P/E ratio | 28 x | 31.9 x | 167 x | 31 x | 45.1 x | 32.6 x | 24.1 x | 22.2 x |
| Yield | - | - | - | - | - | 0.73% | 0.88% | 0.98% |
| Capitalization / Revenue | 1.83 x | 1.82 x | 1.56 x | 1.09 x | 3.06 x | 2.82 x | 2.46 x | 2.24 x |
| EV / Revenue | 2.49 x | 2.69 x | 2.59 x | 2.1 x | 3.98 x | 3.58 x | 3.05 x | 2.24 x |
| EV / EBITDA | 18.5 x | 18.8 x | 24.8 x | 15.8 x | 19.9 x | 18.5 x | 14.8 x | 11.4 x |
| EV / FCF | -9.98 x | -8.58 x | -14.2 x | -26 x | -274 x | 27.4 x | 38.1 x | 19.7 x |
| FCF Yield | -10% | -11.6% | -7.02% | -3.84% | -0.36% | 3.65% | 2.63% | 5.08% |
| Price to Book | 1.8 x | 2.03 x | 2.32 x | 1.72 x | 5.35 x | 4.73 x | 4.09 x | 3.75 x |
| Nbr of stocks (in thousands) | 92,040 | 92,040 | 92,040 | 92,040 | 92,040 | 92,040 | - | - |
| Reference price 2 | 29.70 | 35.05 | 31.65 | 25.45 | 88.30 | 91.50 | 91.50 | 91.50 |
| Announcement Date | 3/15/20 | 2/28/21 | 3/31/22 | 2/26/23 | 3/31/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,497 | 1,772 | 1,873 | 2,152 | 2,653 | 2,982 | 3,426 | 3,764 |
| EBITDA 1 | 201.7 | 253.6 | 195.7 | 286.3 | 532.3 | 578 | 704 | 739.5 |
| EBIT 1 | 103.3 | 126.4 | 54.24 | 140.3 | 342.5 | 430.1 | 504 | 507 |
| Operating Margin | 6.9% | 7.13% | 2.9% | 6.52% | 12.91% | 14.42% | 14.71% | 13.47% |
| Earnings before Tax (EBT) 1 | 102.7 | 106.5 | 24.7 | 81.22 | 201.6 | 274 | 393.2 | 415 |
| Net income 1 | 97.57 | 101 | 17.2 | 75.18 | 180.2 | 263.2 | 352.2 | 425 |
| Net margin | 6.52% | 5.7% | 0.92% | 3.49% | 6.79% | 8.83% | 10.28% | 11.29% |
| EPS 2 | 1.060 | 1.100 | 0.1900 | 0.8200 | 1.960 | 2.808 | 3.802 | 4.130 |
| Free Cash Flow 1 | -372.7 | -554.4 | -340.8 | -173.4 | -38.53 | 389 | 274.5 | 428 |
| FCF margin | -24.9% | -31.28% | -18.2% | -8.06% | -1.45% | 13.04% | 8.01% | 11.37% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 67.3% | 38.99% | 57.88% |
| FCF Conversion (Net income) | - | - | - | - | - | 147.77% | 77.93% | 100.71% |
| Dividend per Share 2 | - | - | - | - | - | 0.6684 | 0.8063 | 0.9000 |
| Announcement Date | 3/15/20 | 2/28/21 | 3/31/22 | 2/26/23 | 3/31/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 498.7 | 498.9 | 513.3 | 508.1 | 512.4 | 618 | 638 | 624.3 | 671 | 719.8 | 726 |
| EBITDA | - | - | 41.44 | - | - | 97.59 | - | - | - | 136.7 | - |
| EBIT 1 | 23.3 | -6.188 | 35.28 | 21.77 | 26.94 | 56.36 | 76.51 | 69 | 109.9 | - | 111.3 |
| Operating Margin | 4.67% | -1.24% | 6.87% | 4.28% | 5.26% | 9.12% | 11.99% | 11.05% | 16.37% | - | 15.34% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - |
| Net income 1 | 14.35 | -18.39 | 20.49 | 10.43 | 11.11 | 33.16 | 50.12 | 40.25 | 53.3 | 36.5 | 58.05 |
| Net margin | 2.88% | -3.69% | 3.99% | 2.05% | 2.17% | 5.37% | 7.86% | 6.45% | 7.94% | 5.07% | 8% |
| EPS 2 | 0.1600 | -0.2000 | - | - | 0.1200 | 0.3600 | 0.5400 | 0.4400 | 0.5800 | 0.4000 | 0.7600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/7/21 | 3/31/22 | 5/15/22 | 8/7/22 | 11/3/22 | 2/26/23 | 5/14/23 | 8/3/23 | 11/9/23 | 3/31/24 | - |
1SAR in Million2SAR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 988 | 1,533 | 1,939 | 2,168 | 2,441 | 2,247 | 2,024 | - |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 4.897 x | 6.044 x | 9.909 x | 7.572 x | 4.585 x | 3.887 x | 2.874 x | - |
| Free Cash Flow 1 | -373 | -554 | -341 | -173 | -38.5 | 389 | 275 | 428 |
| ROE (net income / shareholders' equity) | 6.57% | 6.49% | 1.21% | 5.73% | 12.5% | 13.8% | 18.8% | 22% |
| ROA (Net income/ Total Assets) | 3.23% | 2.78% | 0.43% | 1.77% | 3.73% | 4.5% | 6.45% | 6.5% |
| Assets 1 | 3,016 | 3,631 | 3,965 | 4,237 | 4,836 | 5,850 | 5,461 | 6,538 |
| Book Value Per Share 2 | 16.50 | 17.30 | 13.70 | 14.80 | 16.50 | 19.40 | 22.40 | 24.40 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 471 | 291 | 417 | 249 | 230 | 211 | 207 | 178 |
| Capex / Sales | 31.49% | 16.42% | 22.29% | 11.59% | 8.65% | 7.07% | 6.05% | 4.73% |
| Announcement Date | 3/15/20 | 2/28/21 | 3/31/22 | 2/26/23 | 3/31/24 | - | - | - |
1SAR in Million2SAR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
91.5
SAR
Average target price
84.2
SAR
Spread / Average Target
-7.98%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.62% | 2.24B | |
| -20.16% | 16.21B | |
| +4.50% | 12.44B | |
| +3.98% | 11.58B | |
| +9.72% | 10.79B | |
| -0.10% | 7.68B | |
| +18.43% | 7.2B | |
| +4.49% | 6.67B | |
| +50.89% | 4.66B | |
| -5.12% | 4.25B |
- Stock Market
- Equities
- 4009 Stock
- Financials Middle East Healthcare Company
